News/Resources

News

see all news

Onconetix Announces Two Peer-Reviewed Publications Supporting the Clinical Utility of Proclarix® in early Prostate Cancer Diagnosis and Active Surveillance

May 13, 2026

Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSure

September 22, 2025

Publications

see all publications

Proclarix' performance in ruling out patients with no or indolent prostate cancer: evaluation in a Danish population

Ralph Schiess, Alcibiade Athanasiou, Madlen M E Kasten, Torben F Hansen, Gitte E Kissow, Louise F Obro, Jonna S Madsen, Mads H Poulsen, Palle J Osther, Ahmed H Zedan. BMC Cancer. 2026 May 9. doi: 10.1186/s12885-026-16118-8.

The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort

Alcibiade Athanasiou, Torben F Hansen, Jonna S Madsen, Mads H Poulsen, Mike Allan Mortensen, Gitte E Kissow, Louise F Øbro, Palle J Osther, Ralph Schiess, Ahmed H Zedan. Cancers (Basel). 2026 Apr 23;18(9):1348. doi: 10.3390/cancers18091348.